Update on estrogens and the skeleton.
暂无分享,去创建一个
[1] A. Díez-Pérez,et al. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis , 2006, Osteoporosis International.
[2] J. Cauley,et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Lane,et al. Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.
[4] P. Lønning,et al. Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.
[5] S. Khosla. Increasing options for the treatment of osteoporosis. , 2009, New England Journal of Medicine.
[6] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[7] N. Watts,et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.
[8] S. Manolagas,et al. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. , 2000, Endocrine reviews.
[9] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[10] Roberto Pacifici,et al. Estrogen deficiency and bone loss: an inflammatory tale. , 2006, The Journal of clinical investigation.
[11] D. McDonnell. Mining the complexities of the estrogen signaling pathways for novel therapeutics. , 2003, Endocrinology.
[12] E. Perez,et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .
[13] R. Jilka. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. , 2007, Bone.
[14] F. Collins,et al. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. , 2007, Bone.
[15] Li Han,et al. Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens* , 2005, Journal of Biological Chemistry.
[16] J. Reeve,et al. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. , 1997, The Journal of clinical endocrinology and metabolism.
[17] S. Cummings,et al. Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.
[18] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[19] P. Chambon,et al. Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.
[20] B. L. Riggs,et al. Effect of Blockade of TNF‐α and Interleukin‐1 Action on Bone Resorption in Early Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] J. Krege,et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. , 2009, The Journal of clinical endocrinology and metabolism.
[22] R. Lindsay,et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. , 2009, Fertility and sterility.
[23] R. Marcus. Post-menopausal osteoporosis. , 2002, Best practice & research. Clinical obstetrics & gynaecology.
[24] B. Whitcomb,et al. Long-term impact of the women’s health initiative on HRT , 2008, Archives of Gynecology and Obstetrics.
[25] L. Melton,et al. Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] R. Eastell,et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. , 2000, The Journal of clinical investigation.
[27] A. LaCroix,et al. Lasofoxifene in postmenopausal women with osteoporosis. , 2010, The New England journal of medicine.
[28] S. Khosla. Estrogen and the death of osteoclasts: A fascinating story , 2007 .
[29] S. Cawthorn,et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.
[30] C. Roux,et al. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. , 2009, Best practice & research. Clinical rheumatology.
[31] E. Perez,et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Elevated parathyroid hormone-related peptide associated with lactation and bone density loss , 1996 .
[33] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. King,et al. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. , 1998, The American journal of clinical nutrition.
[35] P. Roberson,et al. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. , 1998, The Journal of clinical investigation.
[36] S. Khosla. Update in male osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.
[37] Sundeep Khosla,et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.
[38] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[39] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[40] J. Wysolmerski,et al. Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. , 2003, Endocrinology.
[41] Jennifer J Westendorf,et al. Building bone to reverse osteoporosis and repair fractures. , 2008, The Journal of clinical investigation.
[42] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[43] S. Cummings,et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.
[44] P. Chambon,et al. The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol , 2009, Proceedings of the National Academy of Sciences.
[45] Mary Jane Geiger,et al. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women , 2006 .
[46] Sundeep Khosla,et al. Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.
[47] P. Lønning,et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] S. Reis,et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2006 .
[49] D. Reid. Prevention of osteoporosis after breast cancer. , 2009, Maturitas.
[50] M. Kulldorff,et al. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.
[51] M. Beckmann,et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] C. Rosen,et al. Developing drugs to treat osteoporosis: lessons learned? , 2010, Expert opinion on pharmacotherapy.
[53] M. Almeida,et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. , 2010, Molecular endocrinology.
[54] G. Constantine,et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. , 2009, Fertility and sterility.